NBIX Stock Price Today (July 2026) — Neurocrine Biosciences, Inc. Analysis & Key Metrics 2026-07-17
Neurocrine Biosciences, Inc. (NBIX) is trading at $170.88, down 0.39% today (as of July 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $195.06 (14.1% upside).
- Volatility remains elevated (19.91% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (42.20% YoY) alongside significant competitive pressures.
NBIX Stock Analysis: Key Metrics & Valuation (July 2026)
Concise, actionable data for investors
Neurocrine Biosciences, Inc. - Historical Price & Volume
Market Cap
Enterprise Value: $16.09B
P/E Ratio
Forward P/E: 13.32
Revenue Growth
Year over Year
Analyst Target
+14.1% upside potential
Key Investor Questions About NBIX
What investors need to know before buying
Based on current market data, NBIX presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 49.63)
- Fundamentals say: Caution warranted (high leverage concerns)
NBIX's growth trajectory depends on its ability to expand within the Drug Manufacturers - Specialty & Generic sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - Specialty & Generic operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for NBIX investors include debt exposure and competitive dynamics in the Drug Manufacturers - Specialty & Generic industry.
- $463.50M in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - Specialty & Generic.
52-Week Trading Range
Over the past year, NBIX stock traded between $122.14 and $171.50—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 19.91% annualized volatility and β=0.85, the stock exhibits moderate correlation to market moves—making NBIX suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Profitable Biotechs Strut Their Stuff As Stock Market Stumbles
AI stocks have come under heavy selling pressure in the stock market, but biotechs are still catching a bid among institutional investors.
Here's Why You Should Add INKT Stock to Your Portfolio Now
MiNK advances agenT-797 across respiratory, oncology and immune disease studies while expanding its next-generation engineered iNKT pipeline.
Zacks.com featured highlights include NVIDIA, Neurocrine Biosciences and Ball
NVIDIA, Neurocrine Biosciences and Ball are highlighted for strong earnings growth, making them stocks to watch in the second half of 2026.
NVIDIA & 2 Best Earnings Growth Stocks to Buy for 2H 2026
NVIDIA, Neurocrine and Ball screen well for earnings growth and rising estimates, highlighting stocks with improving profit expectations.
Summit to Divest Late-Stage Antibiotic Drug to Biossil in $105M Deal
SMMT divests investigational antibiotic ridinilazole to Biossil for upfront cash, milestone payments and royalties as it sharpens its focus on oncology.
Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates?
Neurocrine Biosciences (NBIX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
CG Oncology Stock Gains 12% in Three Months: What's Driving It?
CGON climbs as cretostimogene nears a planned 2026 BLA filing, posts encouraging phase II data. It maintains a cash position that supports operations through 2029.
3 Reasons Why Growth Investors Shouldn't Overlook Neurocrine (NBIX)
Neurocrine (NBIX) possesses solid growth attributes, which could help it handily outperform the market.
Neurocrine Shares Hit Highs on Sales Spike, Strong Pipeline
Biopharmaceutical firm Neurocrine Biosciences, Inc. (NBIX) up over 35% in a year and 17% since outlier inflows in May.
United Therapeutics Stock Rises 14% YTD: Here's What You Need to Know
UTHR's strong clinical wins for Tyvaso and ralinepag, along with progress in organ manufacturing, are boosting growth prospects despite rising PAH competition.
Frequently Asked Questions
Common investor questions about Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. (NBIX) is currently trading at $170.88. The RSI (14-day) is at 49.6, indicating neutral territory. Wall Street analysts have a consensus "strong_buy" recommendation. The mean analyst price target of $195.06 implies 14.1% upside from current levels. Volatility is low at 19.9% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Neurocrine Biosciences, Inc. (NBIX): The trailing P/E ratio is 26.29, which is in line with broader market averages. The forward P/E is 13.32, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 0.48, below 1.0, which generally indicates the stock is undervalued relative to its growth rate. Price-to-Book is 5.04. Price-to-Sales is 5.54. Valuation should be compared to Drug Manufacturers - Specialty & Generic industry peers for context, as different sectors trade at different multiples.
Based on 28 analysts covering NBIX, the consensus price target is $195.06. This represents a 14.1% upside from the current price of $170.88. The range spans from a low target of $144.00 to a high target of $250.65, reflecting varying levels of optimism among analysts. The consensus recommendation is "strong_buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Neurocrine Biosciences, Inc. (NBIX) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Neurocrine Biosciences, Inc. (NBIX) investors include: 1. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 2. Drug Manufacturers - Specialty & Generic sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Neurocrine Biosciences, Inc.'s (NBIX) current debt and financial health profile: Total debt stands at $463.50M. The debt-to-equity ratio is 13.60, which is conservative and indicates a strong balance sheet with low leverage. The current ratio is 2.93, indicating strong short-term liquidity. The quick ratio is 2.51. The company holds $1.32B in cash and equivalents. Free cash flow is positive at $590.55M, providing a cushion for debt servicing and shareholder returns.